Overcoming Resistance to AR-Targeted Therapy in High-Risk Prostate Cancer
Official title: Project 2: Overcoming Microenvironment-Mediated Resistance to AR Pathway Inhibition in High-Risk Prostate Cancer
Funded at Sloan-Kettering Inst Can Research · NIH-11411374 · Data updated 2026-11-12
Researchers are studying why some high-risk prostate cancers stop responding to AR pathway inhibitors and trying new strategies to improve outcomes for men with aggressive, localized disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 14, 2001 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $384,975 |
| NIH project number | 5P50CA092629-25 |
| Project ID | NIH-11411374 on NIH RePORTER |
Who could benefit from this research
✓Could help
Men with high-risk localized or locally advanced prostate cancer who are candidates for AR pathway–targeted therapies.
✕Less likely to help
Patients whose cancer does not rely on AR signaling or does not involve the tumor microenvironment factors studied may not benefit.
What this research studies
This project looks at how the tumor environment around prostate cancer helps cancer cells survive AR-targeted therapies. Using single-cell RNA sequencing in human and mouse samples, scientists will map the interactions between cancer cells and surrounding stromal cells to identify new targets. The goal is to develop combination approaches that boost response rates and move toward potentially curative strategies for high-risk localized disease.
Why it matters
Potential benefit: If successful, the research could lead to more effective treatments that reduce recurrence and improve survival for men with high-risk prostate cancer.
How similar studies have gone: Preclinical work suggests targeting stromal interactions can influence cancer cell survival under AR therapy, with ongoing studies exploring similar approaches.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Carver, Brett Stewart — Sloan-Kettering Inst Can Research
- Study coordinator: Carver, Brett Stewart
Related research
Other NIH-funded projects on the same topics.
-
Tumor environment players in advanced prostate cancer spread
Researchers are studying how the tissue around prostate tumors helps cancer spread, in men with high-risk disease.
-
Integrated genomic and AI pathology biomarkers to guide high-risk prostate cancer treatment
A prostate cancer research project tests how genomic and AI-based pathology tools can help tailor who should receive added ARSI therapy with standard radiotherapy and hormone treatment.
-
Mitochondrial changes in high-risk prostate cancer
This project looks at changes in mitochondrial DNA and cell energy systems in men, especially African American men, with high‑risk prostate cancer to find markers that predict who will develop aggressive disease.
-
Understanding mitochondrial changes in high-risk prostate cancer
This study is looking at how changes in mitochondrial DNA might affect prostate cancer in African American men, who are more likely to face serious cases, with the hope of finding ways to predict and improve treatment for those at risk.
-
How high-risk prostate tumors and nearby cells kick off cancer spread
This project looks at how high-risk prostate tumors and the immune and support cells around them start to spread by using advanced scans and detailed analysis of removed prostate tissue.
-
Blocking stromal signals to make androgen-blocking treatment work better for high-risk prostate cancer
Researchers are trying to improve outcomes for people with high-risk localized prostate cancer by blocking signals from nearby stromal cells so androgen-blocking drugs work more fully.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.